stockmarketproxy
/
JNJNYSE SEC EDGAR

JOHNSON & JOHNSON

Pharmaceutical Preparations·NEW BRUNSWICK, NJ·FY end 01/03·CIK 200406
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$94.2B$88.8B$21.4B$94.9B$93.8B
Gross Profit$63.9B$61.4B$14.6B$63.9B$63.9B
Operating Income——————
Net Income$26.8B$14.1B$4.0B$17.9B$20.9B
Operating CF$24.5B$24.3B$22.8B$21.2B$23.4B
Capex$4.8B$4.4B$4.5B$4.0B$3.7B
Free Cash Flow$19.7B$19.8B$18.2B$17.2B$19.8B
Buybacks$6.0B$2.4B$5.1B$6.0B$3.5B
Dividends——————
Gross Margin67.9%69.1%68.2%67.3%68.2%
Operating Margin——————
Net Margin28.5%15.8%18.9%18.9%22.3%
FCF Margin20.9%22.3%85.3%18.1%21.1%
R&D / Revenue0.1%2.1%2.3%——
Effective Tax17.7%15.7%36.0%17.4%8.3%
Debt / Equity——————
Buybacks / FCF30.2%12.3%27.7%35.1%17.5%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
JNJ
—
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
JNJ
$33M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
JNJ
28.5%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%